US Must Rethink Biologic Naming Suffix, Says IGBA

 
• By Dave Wallace
  
LightBulb
An increasingly isolated US is being urged to rethink its biologic naming approach • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics